A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus

被引：41

作者：

Barber, Katie E. ^{[1
]}

Werth, Brian J. ^{[1
]}

McRoberts, John P. ^{[1
]}

Rybak, Michael J. ^{[1
,2
]}

机构：

[1] Wayne State Univ, Sch Med, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48202 USA

[2] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 05期

关键词：

CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; IN-VITRO MODEL; ANTIMICROBIAL AGENTS; DEVICE; DAPTOMYCIN; VANCOMYCIN; MANAGEMENT; DIAGNOSIS; RIFAMPIN;

D O I：

10.1128/AAC.02764-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Medical device infections frequently require combination therapy. Beta-lactams combined with glycopeptides/lipopeptides are bactericidal against methicillin-resistant Staphylococcus aureus (MRSA). Novel macrowell kill-curve methods tested synergy between ceftaroline or cefazolin plus daptomycin, vancomycin, or rifampin against biofilm-producing MRSA. Ceftaroline combinations demonstrated the most pronounced bacterial reductions. Ceftaroline demonstrated greatest kill with daptomycin (4.02 +/- 0.59 log(10) CFU/cm(2)), compared to combination with vancomycin (3.36 +/- 0.35 log(10) CFU/cm(2)) or rifampin (2.68 +/- 0.61 log(10) CFU/cm(2)). These data suggest that beta-lactam combinations are useful against MRSA biofilms.

引用

页码：2989 / 2992

页数：4

共 25 条

[1]

American Society for Microbiology, ANTIMICROB AGENTS CH, V52, P1

[2] Mutation of sarA in Staphylococcus aureus limits biofilm formation [J].

Beenken, KE ;

Blevins, JS ;

Smeltzer, MS .

INFECTION AND IMMUNITY, 2003, 71 (07) :4206-4211

[3] IN-VIVO VERIFICATION OF IN-VITRO MODEL OF ANTIBIOTIC-TREATMENT OF DEVICE-RELATED INFECTION [J].

BLASER, J ;

VERGERES, P ;

WIDMER, AF ;

ZIMMERLI, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1134-1139

[4] The MBEC assay system: Multiple equivalent biofilms for antibiotic and biocide susceptibility testing [J].

Ceri, H ;

Olson, M ;

Morck, D ;

Storey, D ;

Read, R ;

Buret, A ;

Olson, B .

MICROBIAL GROWTH IN BIOFILMS, PT B: SPECIAL ENVIRONMENTS AND PHYSICOCHEMICAL ASPECTS, 2001, 337 :377-385

[5] The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].

Ceri, H ;

Olson, ME ;

Stremick, C ;

Read, RR ;

Morck, D ;

Buret, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776

[6] ADHERENCE OF COAGULASE-NEGATIVE STAPHYLOCOCCI TO PLASTIC TISSUE-CULTURE PLATES - A QUANTITATIVE MODEL FOR THE ADHERENCE OF STAPHYLOCOCCI TO MEDICAL DEVICES [J].

CHRISTENSEN, GD ;

SIMPSON, WA ;

YOUNGER, JJ ;

BADDOUR, LM ;

BARRETT, FF ;

MELTON, DM ;

BEACHEY, EH .

JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 22 (06) :996-1006

[7] Biofilms: Survival mechanisms of clinically relevant microorganisms [J].

Donlan, RM ;

Costerton, JW .

CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :167-+

[8] In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates [J].

Frank, Kristi L. ;

Reichert, Emily J. ;

Piper, Kerryl E. ;

Patel, Robin .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) :888-895

[9] Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces [J].

Gross, M ;

Cramton, SE ;

Götz, F ;

Peschel, A .

INFECTION AND IMMUNITY, 2001, 69 (05) :3423-3426

[10] Bacterial biofilms: From the natural environment to infectious diseases [J].

Hall-Stoodley, L ;

Costerton, JW ;

Stoodley, P .

NATURE REVIEWS MICROBIOLOGY, 2004, 2 (02) :95-108

← 1 2 3 →